Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-018-28987-6 http://scihub22266oqcxt.onion/10.1038/s41598-018-28987-6 C6048142!6048142!30013230     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2018 ; 8 (ä): ä Nephropedia Template TP {{tp|p=30013230|t=2018. A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity |pdf=|usr=}}{{30013230}} gab.com Text A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=30013230 #FOAvip Intravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations. Thus, there are concerns about systemic complications, in these premature infants who are developing vital organ systems. This study is to determine whether a low dosage (0.15?mg/0.015?mL) of IVC is effective in the treatment of Zone II Stage 2/3?+?ROP. A total of 38 eyes of 20 infants were analyzed retrospectively. We identified treatment effectiveness as complete regression of retinopathy and retinal vascularisation to zone III. The mean gestational age (GA), postmenstrual age (PMA) at treatment and birth weights (BW) were 28.6?±?2.2 weeks, 39.3?±?3.0 weeks and 1297.5?±?429.2?g respectively. Primary effectiveness (react to IVC 0.15?mg alone) was found in 32/38 eyes (84.2%). Secondary effectiveness (a second IVC was required) was found in 6/38 eyes (15.8%). Follow-up continued until 90 weeks? postmenstrual age and showed no recurrences of plus disease or neovascularization. The study suggests 0.15?mg IVC is effective for Zone II Stage 2/3?+?ROP, and there is no adverse ocular outcomes during the follow-up period. Twit Text FOAVip A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=30013230 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30013230 #FOAvip English Wikipedia <ref>{{Cite pmid|30013230}}</ref> A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity #MMPMID30013230 Cheng Y; Meng Q; Linghu D; Zhao M; Liang J Sci Rep 2018[]; 8 (ä): ä PMID30013230show ga Intravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations. Thus, there are concerns about systemic complications, in these premature infants who are developing vital organ systems. This study is to determine whether a low dosage (0.15?mg/0.015?mL) of IVC is effective in the treatment of Zone II Stage 2/3?+?ROP. A total of 38 eyes of 20 infants were analyzed retrospectively. We identified treatment effectiveness as complete regression of retinopathy and retinal vascularisation to zone III. The mean gestational age (GA), postmenstrual age (PMA) at treatment and birth weights (BW) were 28.6?±?2.2 weeks, 39.3?±?3.0 weeks and 1297.5?±?429.2?g respectively. Primary effectiveness (react to IVC 0.15?mg alone) was found in 32/38 eyes (84.2%). Secondary effectiveness (a second IVC was required) was found in 6/38 eyes (15.8%). Follow-up continued until 90 weeks? postmenstrual age and showed no recurrences of plus disease or neovascularization. The study suggests 0.15?mg IVC is effective for Zone II Stage 2/3?+?ROP, and there is no adverse ocular outcomes during the follow-up period. äA lower dose of intravitreal conbercept effectively treats retinopathy(epmc).pdf DeepDyve Pubget Overpricing